Johnson & Johnson reported a 73% PSA response rate in a 15-patient Phase 1 trial of its dual bispecific antibody combo for ...

A comprehensive review published in Genes and Environment examines the complex relationship between tobacco smoking and ...

First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer ...

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has just paid off with an FDA approval for Pluvicto, the first targeted radioligand therapy ...

A narrative review in the African Journal of Urology outlines adaptive strategies for managing metastatic prostate cancer in ...

Sports247 reports that the member of Nigeria’s 1980 Africa Cup of Nations winning team on home soil in Lagos, who has played ...

Adding darolutamide (Nubeqa) to androgen deprivation therapy (ADT) and radiation therapy significantly improved metastasis-free survival in patients with very high-risk prostate cancer, according to ...

Lung cancer remains the leading cause of cancer death in the U.S. and sits at the intersection of several pressures health systems are already managing: an aging patient population, uneven access to ...

Stakeholders in Nigeria stress the need for early cancer detection and prompt treatment, warning that delays reduce survival chances and worsen the disease ...

Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

Scientists hope to double survival rates for patients with the deadliest blood cancers by adopting a trial approach that has ...